INmune Bio Submits Its CORDStrom Platform Patent Application Into The U.S. National Phase Before USPTO

Submission advances a key element of the Company’s global intellectual property strategy for its next-generation mesenchymal stromal cell (MSC) platform.

Highlights Advanced to U.S.

National Phase: The Company has officially transitioned its CORDStrom™ platform patent application into the U.S. national phase before the USPTO, solidifying its proprietary footprint in the world's largest healthcare market.

De-Risked via Favorable PCT Written Opinion: During the international phase, the corresponding Patent Cooperation Treaty (PCT) application received a favorable Written Opinion regarding patentability, significantly validating the novelty, inventiveness, and strength of the underlying asset architecture prior to national entry.

Broad Platform-Wide Protection: The application directly targets the Company’s CORDStrom™ mesenchymal stromal cell (MSC) platform, protecting Ebstrocel (pobistrocel) for epidermolysis bullosa (EB) alongside next-generation modalities designed to select MSCs based on disease-specific biology or engineer them to deliver targeted therapeutic payloads.

Extended Commercial Runway: If granted, this foundational patent family is projected to provide exclusive commercial protection extending into at least 2045, establishing multi-decade market exclusivity and safeguarding long-term asset valuation.

Global Expansion Strategy: In alignment with its international commercialization goals, the Company expects to pursue corresponding national and regional patent applications across additional high-value jurisdictions, including the United Kingdom, Europe, Asia, Latin America and other primary global markets.

The U.S. national phase filing follows a favorable Written Opinion received during the international phase of the corresponding PCT application.

The patent application is directed to the Company’s CORDStrom™ MSC platform, including Ebstrocel (pobistrocel) for epidermolysis bullosa (EB), as well as additional CORDStrom™ modalities in which MSCs are selected based on disease-specific biological characteristics and may be engineered to deliver targeted therapeutic payloads.

The CORDStrom™ platform addresses historical industry bottlenecks such as donor-to-donor variability and batch manufacturing inconsistencies by leveraging a proprietary selection and pooled, allogeneic, human umbilical cord-derived framework.

This newly advanced patent application protects not only the core therapeutic compositions but also the specialized engineering methodologies required to utilize MSCs as selective delivery vehicles for complex therapeutic payloads, creating an expansive defensive moat around the Company's cell therapy pipeline.